[HTA-pre-eclampsia-postpartum haemolytic-uraemic syndrome: good results can be achieved].
Santos Nores
J
J
Bravo López
J J
JJ
Borrajo Prol
M P
MP
Iglesias Forneiro
A
A
D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002585:Cesarean Section; D003131:Combined Modality Therapy; D004630:Emergencies; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007741:Labetalol / Q000627:therapeutic use; D008750:Methyldopa / Q000627:therapeutic use; D010956:Plasmapheresis; D011225:Pre-Eclampsia / Q000188:drug therapy / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use; D011247:Pregnancy; D011644:Puerperal Disorders / Q000188:drug therapy / Q000628:therapy*; D012074:Remission Induction
D047228:Angiotensin II Type 1 Receptor Blockers; D000893:Anti-Inflammatory Agents; D000959:Antihypertensive Agents; D008750:Methyldopa; D007741:Labetalol; D011241:Prednisone